Advancing Eyecare Revenue and Competitors
Estimated Revenue & Valuation
- Advancing Eyecare's estimated annual revenue is currently $26.1M per year.
- Advancing Eyecare's estimated revenue per employee is $251,000
Employee Data
- Advancing Eyecare has 104 Employees.
- Advancing Eyecare grew their employee count by 55% last year.
Advancing Eyecare's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | President and Chief Strategy Officer | Reveal Email/Phone |
4 | Global Chief Operating Officer | Reveal Email/Phone |
5 | Chief Sales Officer (CSO) | Reveal Email/Phone |
6 | Chief Operating Officer | Reveal Email/Phone |
7 | VP Sales | Reveal Email/Phone |
8 | VP Corporate Development | Reveal Email/Phone |
9 | VP, Global Marketing | Reveal Email/Phone |
10 | VP Tax | Reveal Email/Phone |
Advancing Eyecare Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $26.1M | 104 | 0% | $63.5M | N/A |
#2 | $14.3M | 54 | 15% | N/A | N/A |
#3 | $33.1M | 117 | 8% | N/A | N/A |
#4 | $10.8M | 46 | 31% | N/A | N/A |
#5 | $488.3M | 1216 | 0% | N/A | N/A |
#6 | $14.3M | 44 | -6% | N/A | N/A |
#7 | $5M | 20 | -9% | N/A | N/A |
#8 | $95.6M | 306 | -2% | N/A | N/A |
#9 | $16.8M | 60 | 9% | N/A | N/A |
#10 | $57M | 275 | 22% | N/A | N/A |
What Is Advancing Eyecare?
Advancing Eyecare is a wholly-owned portfolio company of Atlantic Street Capital. The group is comprised of a powerful alliance of leading ophthalmic instrument providers in North America, including Lombart Instrument, INNOVA Medical Ophthalmics, Enhanced Medical Services, and Marco Ophthalmic.
keywords:N/AN/A
Total Funding
104
Number of Employees
$26.1M
Revenue (est)
55%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.5M | 104 | 8% | N/A |
#2 | $26.5M | 104 | 13% | N/A |
#3 | $30.2M | 104 | 58% | N/A |
#4 | N/A | 104 | 32% | N/A |
#5 | $30.2M | 104 | 6% | N/A |